MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2023 International Congress

August 27-31, 2023. Copenhagen, Denmark.

View by Title View Categories
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Learnings from inaugural year of foundation sponsored genetic counseling and testing program for Spinocerebellar Ataxia (SCA) types 1, 2, and 3

    K. Trace, N. Beck, L. Moore (Minneapolis, USA)

  • Left hemisphere theta coherence between cortex and STN increases during speech

    A. Nakhmani, R. Smith, V. Del Bene, M. Nelson, J. Olson, S. Brinkerhoff, Z. Irwin, J. Bentley, R. Knight, H. Walker (Birmingham, USA)

  • Leveraging MRI and machine-learning for early detection of cognitive impairment in Parkinson’s disease

    L. Saadatpour, A. Vijayakumari, B. Walter, H. Fernandez (Cleveland, USA)

  • Levodopa Carbidopa Intestinal Gel for Parkinson’s Disease over 11 years: A Single Center “Real-World” Experience

    C. Vekhande, M. Hamed, G. Tremain, J. Mah, A. Shetty, A. Lazarescu, O. Suchowersky (Edmonton, Canada)

  • Levodopa-carbidopa intestinal gel for managing severe refractory tremors of idiopathic Parkinson’s disease: Case Series

    M. Abu Al-Melh, N. Abdelall, T. Al-Otaibi (Ahmadi governorate, Kuwait)

  • Levodopa-Entacapone-Carbidopa Intestinal Gel in advanced Parkinson’s disease: a single center experience

    V. Constantin, S. Szatmari, K. Orban-Kis, S. Bataga, R. Neagoe, M. Ciorba, I. Mihaly, K. Kelemen, J. Szasz (Targu Mures, Romania)

  • Levodopa-entacapone-carbidopa intestinal gel infusion for Parkinson’s disease: An analysis of data collected from the Swedish national register of Parkinson’s disease.

    M. öthman, P. Odin, F. Bergquist, A. Johansson, R. Constantinescu, M. Scharfenort, H. Widner, D. Nyholm (Uppsala, Sweden)

  • Levodopa-entacapone-carbidopa-infusion treatment in Parkinson’s disease: A six-month follow-up study

    V. Viljaharju, T. Mertsalmi, KAM. Pauls, M. Koivu, J. Eerola-Rautio, M. Udd, E. Pekkonen (Helsinki, Finland)

  • Levodopa-induced dyskinesia and Huntington’s chorea: link to current motor control theories

    JF. Daneault, Y. Liu, J. Miranda, C. Duval, M. Chen, S. Lee (Newark, USA)

  • Levodopa-induced orthostatic hypotension in a large cohort of patients with Parkinson’s disease undergoing an acute levodopa challenge test

    X. Wang, S. Mei, C. Han, P. Chan (Beijing, China)

  • « Previous Page
  • 1
  • …
  • 99
  • 100
  • 101
  • 102
  • 103
  • …
  • 186
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
  • #26133 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley